AKUMS
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Akums Drugs gains; Citi initiates with a "buy"
** Shares of Akums Drugs AKUM.NS rise 2.1% to 519 rupees apiece
** Citi Research initiates coverage of the co, which is a contract development and manufacturing organisation (CDMO), with "buy"
** Brokerage sets PT of 700 rupees, implying a 12-month return of 37.8%
** Says AKUM has an edge over competition in terms of scale, manufacturing capabilities
** Adds recent weakness due to correction in the prices of active pharma ingredients (API) will be transient, expects recovery in fiscal 2026 and 2027
** AKUM's 100-million-euro CDMO contract from a global pharma company will aid earnings, showcases potential to make inroads in international markets, says Citi
** AKUM shares down 19% in 2025 so far, nearly twice as much as the 9.5% drop in Nifty 500 index .NIFTY500 - data compiled by LSEG
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
** Shares of Akums Drugs AKUM.NS rise 2.1% to 519 rupees apiece
** Citi Research initiates coverage of the co, which is a contract development and manufacturing organisation (CDMO), with "buy"
** Brokerage sets PT of 700 rupees, implying a 12-month return of 37.8%
** Says AKUM has an edge over competition in terms of scale, manufacturing capabilities
** Adds recent weakness due to correction in the prices of active pharma ingredients (API) will be transient, expects recovery in fiscal 2026 and 2027
** AKUM's 100-million-euro CDMO contract from a global pharma company will aid earnings, showcases potential to make inroads in international markets, says Citi
** AKUM shares down 19% in 2025 so far, nearly twice as much as the 9.5% drop in Nifty 500 index .NIFTY500 - data compiled by LSEG
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
Akums Drugs And Pharmaceuticals Says Tax Department Conducts Search
Jan 22 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:
AKUMS DRUGS AND PHARMACEUTICALS - INCOME TAX DEPARTMENT CONDUCTS SEARCH AT AKUMS OFFICES AND UNITS
AKUMS DRUGS AND PHARMACEUTICALS LTD - BUSINESS OPERATIONS CONTINUE AS USUAL WITH MINOR HICCUPS
Source text: ID:nBSE5577PC
Further company coverage: AKUM.NS
(([email protected];))
Jan 22 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:
AKUMS DRUGS AND PHARMACEUTICALS - INCOME TAX DEPARTMENT CONDUCTS SEARCH AT AKUMS OFFICES AND UNITS
AKUMS DRUGS AND PHARMACEUTICALS LTD - BUSINESS OPERATIONS CONTINUE AS USUAL WITH MINOR HICCUPS
Source text: ID:nBSE5577PC
Further company coverage: AKUM.NS
(([email protected];))
Akums Drugs Ties Up With Jagdale
Nov 26 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:
AKUMS DRUGS - TIES UP WITH JAGDALE FOR MARKETING READY TO DRINK NUTRITIONAL BEVERAGES
Source text: ID:nBSE2tT0S5
Further company coverage: AKUM.NS
(([email protected];))
Nov 26 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:
AKUMS DRUGS - TIES UP WITH JAGDALE FOR MARKETING READY TO DRINK NUTRITIONAL BEVERAGES
Source text: ID:nBSE2tT0S5
Further company coverage: AKUM.NS
(([email protected];))
India's Akum Drugs rises on agreement with South Korean co
** Akum Drugs and Pharmaceuticals AKUM.NS rises to exchange-allowed upper circuit of 5% to 580.7 rupees
** Co enters into agreement with Caregen 214370.KQ, a South Korean firm that makes cosmeceuticals and dermal fillers
** Deal grants Akum exclusive rights to sell certain Caregen products in India
** Stock set to snap 10 sessions of losses
** About 2.3 mln shares traded, 10.4x 30-day avg
** AKUM down 23.7% since listing on Aug. 6, as of last close
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
** Akum Drugs and Pharmaceuticals AKUM.NS rises to exchange-allowed upper circuit of 5% to 580.7 rupees
** Co enters into agreement with Caregen 214370.KQ, a South Korean firm that makes cosmeceuticals and dermal fillers
** Deal grants Akum exclusive rights to sell certain Caregen products in India
** Stock set to snap 10 sessions of losses
** About 2.3 mln shares traded, 10.4x 30-day avg
** AKUM down 23.7% since listing on Aug. 6, as of last close
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
Akums Drugs And Pharmaceuticals Executes License & Distribution Agreement With Triple Hair
Oct 16 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:
EXECUTION OF LICENSE & DISTRIBUTION AGREEMENT WITH TRIPLE HAIR
Source text for Eikon: ID:nBSE7M3QCt
Further company coverage: AKUM.NS
(([email protected];))
Oct 16 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:
EXECUTION OF LICENSE & DISTRIBUTION AGREEMENT WITH TRIPLE HAIR
Source text for Eikon: ID:nBSE7M3QCt
Further company coverage: AKUM.NS
(([email protected];))
Akums Drugs Launches Famotidine, Calcium Carbonate, Magnesium Hydroxide In India
Oct 9 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:
LAUNCHES FAMOTIDINE, CALCIUM CARBONATE, MAGNESIUM HYDROXIDE IN INDIA
Source text for Eikon: ID:nNSE5PN7K9
Further company coverage: AKUM.NS
(([email protected];;))
Oct 9 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:
LAUNCHES FAMOTIDINE, CALCIUM CARBONATE, MAGNESIUM HYDROXIDE IN INDIA
Source text for Eikon: ID:nNSE5PN7K9
Further company coverage: AKUM.NS
(([email protected];;))
Events:
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Akums Drugs & Pharma do?
Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, the company owns the intellectual property for the manufacturing processes of several of its formulations, and its core business is focused on providing end-to-end product development and manufacturing solutions to its clients.
Who are the competitors of Akums Drugs & Pharma?
Akums Drugs & Pharma major competitors are FDC, Strides Pharma Scien, Aarti Pharmalabs, Shilpa Medicare, Suven Life Sciences, Marksans Pharma, Medplus Health Servi. Market Cap of Akums Drugs & Pharma is ₹7,696 Crs. While the median market cap of its peers are ₹7,736 Crs.
Is Akums Drugs & Pharma financially stable compared to its competitors?
Akums Drugs & Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Akums Drugs & Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Akums Drugs & Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Akums Drugs & Pharma allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments
How strong is Akums Drugs & Pharma balance sheet?
Balance sheet of Akums Drugs & Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Akums Drugs & Pharma improving?
The profit is oscillating. The profit of Akums Drugs & Pharma is ₹338 Crs for Mar 2025, -₹4.04 Crs for Mar 2024 and ₹94.86 Crs for Mar 2023
Is the debt of Akums Drugs & Pharma increasing or decreasing?
The net debt of Akums Drugs & Pharma is decreasing. Latest net debt of Akums Drugs & Pharma is -₹1,138.75 Crs as of Mar-25. This is less than Mar-24 when it was -₹62.22 Crs.
Is Akums Drugs & Pharma stock expensive?
Akums Drugs & Pharma is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Akums Drugs & Pharma is 23.41, while 3 year average PE is 5.88. Also latest EV/EBITDA of Akums Drugs & Pharma is 15.84 while 3yr average is 23.39.
Has the share price of Akums Drugs & Pharma grown faster than its competition?
Akums Drugs & Pharma has given lower returns compared to its competitors. Akums Drugs & Pharma has grown at ~-38.17% over the last 1yrs while peers have grown at a median rate of 16.52%
Is the promoter bullish about Akums Drugs & Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Akums Drugs & Pharma is 75.26% and last quarter promoter holding is 75.26%.
Are mutual funds buying/selling Akums Drugs & Pharma?
The mutual fund holding of Akums Drugs & Pharma is increasing. The current mutual fund holding in Akums Drugs & Pharma is 6.73% while previous quarter holding is 6.11%.